Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABFRA:61MA -0.22%91 PS Ratio is 3.44 as of Jul. 17, 2026, which is 16% above its 10-year median of 2.96. GuruFocus rates FRA:61MA with a GF Score™ of 91/100 and a GF Value™ of €50.10 (Fairly Valued). Among 805 Medical Devices & Instruments companies, MedCap AB ranks worse than 58.14% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MedCap AB's share price is €45.54.
MedCap AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €13.25. Hence, MedCap AB's PS Ratio for today is 3.44.
Good Sign:
MedCap AB stock PS Ratio (=3.46) is close to 1-year low of 3.23.
The historical rank and industry rank for MedCap AB's PS Ratio or its related term are showing as below:
FRA:61MA'
s PS Ratio Range Over the Past 10 Years
Min: 0.44 Med: 2.96 Max: 5.23
Current: 3.49
During the past 13 years, MedCap AB's highest PS Ratio was 5.23. The lowest was 0.44. And the median was 2.96.
FRA:61MA's PS Ratio is ranked worse than 58.14% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs FRA:61MA: 3.49
During the past 12 months, the average Revenue per Share Growth Rate of MedCap AB was 17.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 23.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 21.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.60% per year.
During the past 13 years, MedCap AB's highest 3-Year average Revenue per Share Growth Rate was 36.20% per year. The lowest was -5.90% per year. And the median was 17.60% per year.
Back to Basics: PS Ratio
MedCap AB (FRA:61MA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
MedCap AB PS Ratio Related Terms
MedCap AB PS Ratio Historical Data
* Premium members only.
The historical data trend for MedCap AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MedCap AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where MedCap AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
MedCap AB's Share Price of today is €45.54. MedCap AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
MedCap AB (FRA:61MA) has a PS Ratio of 3.44 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MedCap AB and its competitors. This is 16% above median its historical median of 2.96. Over the past decade, MedCap AB's PS Ratio has ranged from 0.44 to 5.23. According to the industry distribution chart, MedCap AB ranks #468 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 58.1%.
Is MedCap AB's PS Ratio too high?
MedCap AB's current PS Ratio of 3.44 is 16% above median its 10-year median of 2.96. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 5.23. The Medical Devices & Instruments industry median PS Ratio is 2.86. MedCap AB's value of 3.44 is 20.3% above this industry median. Based on the distribution chart, MedCap AB ranks #468 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MedCap AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #468 out of 805 companies for PS Ratio. This places MedCap AB in the lower half of its industry. The industry median PS Ratio is 2.86. MedCap AB's value of 3.44 is 20.3% above this benchmark. Historically, MedCap AB's own PS Ratio has ranged from 0.44 to 5.23 over the past decade. While the company's 10-year median is 2.96 vs. the industry median of 2.86, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current PS Ratio of 3.44 is 20.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current PS Ratio is 3.44, which is 16% above median its own 10-year median of 2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (FRA:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €50.10, compared to a current price of €45.54 — trading 9.1% below its estimated fair value. The current PS Ratio is 3.44, which is 16% above median its 10-year median of 2.96 and 20.3% above the Medical Devices & Instruments industry median of 2.86. MedCap AB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For MedCap AB (FRA:61MA), the current PS Ratio is 3.44 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (FRA:61MA) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of €45.54 is trading 9.1% below its estimated GF Value™ of €50.10.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for FRA:61MA:
PS Ratio: 3.44 (16% above median its 10-year median of 2.96)
GF Value™: €50.10 vs. price of €45.54 (9.1% below fair value)
Industry Position: 20.3% above the Medical Devices & Instruments median (#468 of 805)
No single metric tells the full story. See the FRA:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
91GF Score
Get the complete analysis for FRA:61MA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61MA has been successfully added to your 
